ProStar Rings the Opening Bell on the Toronto Stock Exchange | INN

ProStar Holdings Inc ("ProStar" or the "Company") (TSXV: MAPS) is pleased to report that the Company's CEO and Founder, Page Tucker and the ProStar team joined Arne Gulstene, Head, Company Services, TMX Group, to celebrate the Company's listing on the Toronto Stock Exchange (TSX) Venture Exchange by ringing the bell to open the market today.

ProStar™ is a world leader in Precision Mapping Solutions™. The Company's flagship product, PointMan ^® , improves the business operations of industries involved in the construction, maintenance, upgrade and repair of surface and subsurface infrastructure. ProStar's clients include Fortune 500 construction firms, government agencies, energy companies, and engineering and surveying firms in North America and Europe.

"For any company it would be considered an honor and a privilege to ring the opening bell, and today is no exception," said Page Tucker , CEO and founder of ProStar. "This occasion marks a major milestone for us that required a great deal of effort and commitment from so many stakeholders as well as the TMX and albeit a virtual event due to the pandemic, it is still a momentous occasion."

What You Should Know About ProStar (TSXV: MAPS)(FSE: 5D00)

ProStar is a world leader in Precision Mapping Solutions™. ProStar's flagship product, PointMan, is natively cloud and mobile, offered as a Software as a Solution (SaaS). ProStar's solutions are being adopted by some of the largest entities in North America , including Fortune 500 construction firms, the largest subsurface utilities engineering (SUE) firms, and government agencies.

ProStar's strategic partnerships are with leading geospatial technology and data collection equipment manufactures and their dealer networks, including Trimble ^® (NASDAQ: TRMB), Juniper ^® Systems, Vivax-Metrotech, Radiodetection ^® , and Subsite ^® Electronics.

The company has made a significant investment in creating a vast intellectual property portfolio that includes 19 issued patents in the United States and Canada , with more pending. The patents protect the methods and systems required to digitally capture, record, organize, manage, distribute, and display the precise location of buried utilities and pipelines.

ProStar's Executive management team has extensive experience in both early stage and Fortune 500 companies, TSX and TSX.V listed enterprises, and in geospatial, cloud and mobile technologies. ProStar's leadership team includes Vasa Dasan, former CTO of Sun Microsystems, Carl Lashua , previous Chief Information Officer of HSBC Canada and Europe , and Matthew Breman prior Executive for Disney.

For more information about ProStar, please visit: www.prostarcorp.com .

Contact

Alex Moore
Investor Relations Support
investorrelations@prostarcorp.com
970-242-4024

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking information within the meaning of Canadian securities laws. Such information includes, without limitation, information regarding the terms and conditions of the Company's future plans. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward-looking information is typically identified by words such as: "believe", "expect", "anticipate", "intend", "estimate", "postulate" and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's securities; the state of the technology sector; recent market volatility; the COVID-19 pandemic; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; and other risks and factors that the Company is unaware of at this time. The reader is referred to the Company's recent Information Circular filed on SEDAR on November 20, 2020 for a more complete discussion of applicable risk factors and their potential effects, copies of which may be accessed through the Company's issuer page on SEDAR at www.sedar.com .

The forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia: https://www.prnewswire.com/news-releases/prostar-rings-the-opening-bell-on-the-toronto-stock-exchange-301241576.html

SOURCE ProStar Corp

View original content to download multimedia: https://www.newswire.ca/en/releases/archive/March2021/05/c6226.html

News Provided by Canada Newswire via QuoteMedia

ProStar™ GeoCorp TSXV:MAPS Emerging Tech Investing

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Zero Candida Technologies Inc. Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News